Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial - Stouten, V
Ann Rheum Dis 2021 annrheumdis- 2020-219825. doi:10.1136/annrheumdis- 2020-219825